Nanoformulation Improves Activity of the (pre)Clinical Anticancer Ruthenium Complex KP1019

Heffeter, Petra; Riabtseva, Anna; Senkiv, Julia; Kowol, Christian R.; Körner, Wolfgang; Jungwith, U; Mitina, Nataliya; Keppler, Bernhard K.; Konstantinova, T K; Yanchuk, I. B.; Stoika, Rostyslav; Zaichenko, Alexander; Berger, Walter

doi:10.1166/jbn.2014.1763

Cited by 44 publications

(31 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Two typical Ru(III)-drugs [ImH][trans-RuCl 4 (DMSO)(Im)] (NAMI-A) and [IndH][trans-RuCl 4 (Ind) 2 ] (KP1019) have successfully entered clinical trials [2–4]. However, more detailed investigation of the antitumor mechanism of these ruthenium compounds still remains largely speculative [5–9].…”

Section: Introductionmentioning

confidence: 99%

The induction of autophagy against mitochondria-mediated apoptosis in lung cancer cells by a ruthenium (II) imidazole complex

Chen

Peng

et al. 2016

Oncotarget

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

The induction of autophagy against mitochondria-mediated apoptosis in lung cancer cells by a ruthenium (II) imidazole complex

Chen

Peng

et al. 2016

Oncotarget

View full text Add to dashboard Cite

show abstract

“…Micelles delivering metallodrugs have been investigated [55][56][57][58][59][60]. One strategy involved the covalent attachment of the drug directly to the micelle to avoid its premature release in the circulation [55][56][57][58][59].…”

Section: Micellesmentioning

confidence: 99%

Nano-Based Systems and Biomacromolecules as Carriers for Metallodrugs in Anticancer Therapy

2018

View full text Add to dashboard Cite

Since the discovery of cisplatin and its potency in anticancer therapy, the development of metallodrugs has been an active area of research. The large choice of transition metals, oxidation states, coordinating ligands, and different geometries, allows for the design of metal-based agents with unique mechanisms of action. Many metallodrugs, such as titanium, ruthenium, gallium, tin, gold, and copper-based complexes have been found to have anticancer activities. However, biological application of these agents necessitates aqueous solubility and low systemic toxicity. This minireview highlights the emerging strategies to facilitate the in vivo application of metallodrugs, aimed at enhancing their solubility and bioavailability, as well as improving their delivery to tumor tissues. The focus is on encapsulating the metal-based complexes into nanocarriers or coupling to biomacromolecules, generating efficacious anticancer therapies. The delivery systems for complexes of platinum, ruthenium, copper, and iron are discussed with most recent examples. explored as possible alternatives, but none have yet entered the clinic. Importantly, high efficacy of platinum paved the way for the development of other transition metal complexes, many with outstanding cytotoxic properties against cancer cells.Transition metals form complexes of multiple geometries based on the number of coordination sites, offering a stereoisomeric diversity higher than carbon. In addition, a synthesis of metallodrugs requires fewer steps when compared to organic compounds. This is accompanied by a myriad choice of coordinating ligands [17] facilitating fine-tuning the properties of metal-based complexes [17,18]. The octahedral titanium species cis-diethoxy-bis(1-phenylbutane-1,3-dionato)titanium(IV) [(bzac) 2 Ti(OEt) 2 ] (budotitane), was the first non-Pt(II) metal compound that reached clinical trials [19]. Following this, ruthenium-based complexes were explored showing fewer side effects when compared to platinum-based agents and activity against Pt-resistant cancers [20][21][22]. Two ruthenium derivates, imidazolium trans-DMSO-imidazole-tetrachlororuthenate (NAMI-A) and imidazolium trans-[tetrachlorido(DMSO)(1H-imidazole)ruthenate(III)] (KP-1019), have been tested in clinical trials [22,23]. KP-1019 showed efficacy towards primary tumors, such as colon cancer, without triggering systemic toxicity, while NAMI-A was not cytotoxic but demonstrated activity against metastases. Moreover, NKP-1339 (the sodium salt analogue of KP1019, sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)]) has successfully completed a phase I clinical trial [24]. NKP-1339 is Ru(III) that binds to serum proteins albumin and transferrin, which transport and deliver the metallodrug to the tumor tissue. Once inside endosomes, NKP-1339 reduces to Ru(II). Recently, new designs of ruthenium complexes are emerging that include Ru(η 5 -C 5 H 5 ) core. This class of Ru(II) compounds demonstrates enhanced selectivity and effectiveness, for example ruthenium pyridocarbazole (DW1/2...

show abstract

“…It was found that nanocomplexation of TMZ increased approximately twice its antipro- liferative activity. It could be due to the selectively increase of the drug accumulation in tumor cells and slow drug release into the interstitial space of the tumor [18,19]. Application of such kind of complex stimulates the cells to accumulate the drug by endocytosis pathway and by macropinocytosis pathway.…”

Section: Fig 7 Ratio Of Dead Cells Treated For 72 H With Free Temozmentioning

confidence: 99%

Modulation of temozolomide action towards rat and human glioblastoma cells in vitro by its combination with doxorubicin and immobilization with nanoscale polymeric carrier

Finiuk¹,

Senkiv²,

Riabtseva³

2016

Ukr.Biochem.J.

View full text Add to dashboard Cite

Nanoformulation Improves Activity of the (pre)Clinical Anticancer Ruthenium Complex KP1019

Cited by 44 publications

References 0 publications

The induction of autophagy against mitochondria-mediated apoptosis in lung cancer cells by a ruthenium (II) imidazole complex

The induction of autophagy against mitochondria-mediated apoptosis in lung cancer cells by a ruthenium (II) imidazole complex

Nano-Based Systems and Biomacromolecules as Carriers for Metallodrugs in Anticancer Therapy

Modulation of temozolomide action towards rat and human glioblastoma cells in vitro by its combination with doxorubicin and immobilization with nanoscale polymeric carrier

Contact Info

Product

Resources

About